KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • RAS (Rat Sarcoma Virus)

KRAS mutation • NRAS mutation • RAS mutation

Capoxigem (apricoxib) • TG01 vaccine

over1year

The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma (clinicaltrials.gov)

P1/2, N=20, Not yet recruiting, Oslo University Hospital

over 1 year ago

New P1/2 trial

KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RAS (Rat Sarcoma Virus)

KRAS mutation • NRAS mutation • RAS mutation

Capoxigem (apricoxib) • TG01 vaccine

over3years

Identification of potential candidate genes for lip and oral cavity cancer using network analysis. (PubMed, Genomics Inform)

VEGFA, IL6, MAPK3, INS, TNF, MAPK8, MMP9, CXCL8, EGF, and PTGS2 were recognized as network hub genes using the maximum clique centrality algorithm available in cytoHubba, and nine potential drug candidates (ranibizumab, siltuximab, sulindac, pomalidomide, dexrazoxane, endostatin, pamidronic acid, cetuximab, and apricoxib) for lip and oral cavity cancer were identified from the DGIdb database. Gene enrichment analysis was also performed to identify the gene ontology categorization of cellular components, biological processes, molecular functions, and biological pathways. The genes identified in this study could furnish a new understanding of the underlying molecular mechanisms of carcinogenesis and provide more reliable biomarkers for early diagnosis, prognostication, and treatment of lip and oral cavity cancer.

over 3 years ago

Journal

IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • MMP9 (Matrix metallopeptidase 9) • MAPK3 (Mitogen-Activated Protein Kinase 3) • MAPK8 (Mitogen-activated protein kinase 8)

Erbitux (cetuximab) • pomalidomide • Sylvant (siltuximab) • Capoxigem (apricoxib) • Lucentis (ranibizumab) • dexrazoxane

almost4years

TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial. (PubMed, Br J Cancer)

TG01/GM-CSF with gemcitabine was well tolerated, with high levels of immune activation. OS and DFS compare favourably with published data for adjuvant gemcitabine.

almost 4 years ago

Clinical • P1/2 data • Journal • IO biomarker

KRAS (KRAS proto-oncogene GTPase) • CSF2 (Colony stimulating factor 2)

gemcitabine • Capoxigem (apricoxib)

5years

Multiple KRAS mutations detected by cancer related DNA in patients with resected pancreas adenocarcinoma during treatment with TG01/GM-CSF and gemcitabine (CT TG01-01) (ESMO-IO 2019)

The great majority of patients with PAC have multiple KRAS mutations; in addition, mutations changed during the course of the study. Single mutation vaccines and small molecules targeting single mutations are therefore unlikely to be effective while therapies targeting a mix of KRAS mutations (TG01) may be more beneficial.Legal entity responsible for the study: The authors. Funding: Has not received any funding.

5 years ago

Clinical • IO biomarker

KRAS (KRAS proto-oncogene GTPase) • CSF2 (Colony stimulating factor 2)

gemcitabine • Capoxigem (apricoxib)

almost6years

Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer (clinicaltrials.gov)

P=N/A, N=1, Terminated, Jonsson Comprehensive Cancer Center | N=40 --> 1

almost 6 years ago

Clinical • Enrollment change

IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • FOXP3 (Forkhead Box P3)

TILs

Capoxigem (apricoxib)